SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-7.14%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$300M
AUM Growth
+$300M
(+18%)
Cap. Flow
+$73.2M
Cap. Flow
% of AUM
24.44%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
2
Reduced
–
Closed
4
Top Buys
| 1 |
Biogen
BIIB
|
$20M |
| 2 |
Innoviva
INVA
|
$841K |
Top Sells
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$8.44M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$5.85M |
| 3 |
VVUS
Vivus Inc
VVUS
|
$2.88M |
| 4 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
$598K |
Sector Composition
| 1 | Healthcare | 54.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$19.4B
| $104M | 34.77% | 383,858 +73,858 | +24% | +$20M |
|
|
MDCO
2
DELISTED
Medicines Co
MDCO
| $66.6M | 22.23% | 1,752,000 | – | – |
|
|
3
Innoviva
INVA
$1.29B
| $44.7M | 14.92% | 3,490,705 +65,705 | +2% | +$841K |
|
|
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $9.46M | 3.16% | 1,025,000 | – | – |
|
|
ADXS
5
DELISTED
Advaxis, Inc.
ADXS
| $2.2M | 0.73% | 339,180 | – | – |
|
|
SEEL
6
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $1.64M | 0.55% | 1,447,906 | – | – |
|
7
AbbVie
ABBV
$372B
| $725K | 0.24% | 10,000 | – | – |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – | -360,000 | Closed | -$5.85M |
|
|
AVEO
9
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – | -1,013,616 | Closed | -$598K |
|
|
BIVV
10
DELISTED
Bioverativ Inc. Common Stock
BIVV
| – | – | -155,000 | Closed | -$8.44M |
|
|
VVUS
11
DELISTED
Vivus Inc
VVUS
| – | – | -2,573,943 | Closed | -$2.88M |
|